Potency and toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Hematology and Disorders · 2023
DOI: 10.58489/2836-3582/006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology and Disorders, 2023. Verfasst von Yuting Ma und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cells have opened up a new model for the treatment of relapsed and/or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). However, CAR T cell therapy can cause severe or even fatal related toxicity that impairs the survival benefits of patients. Thus, developing and formulating the standardized clinical management of these toxicities are urgent for medics. Of note, potency and toxicity of CAR-T cells therapy are related to patient and disease features, the CAR-T product and escape of tumor cell. However, the optimal patient selection has not yet been well established.
Zitieren
APA
Ma, Y., Li, N., Lu, J., Yang, P., Li, P., Zhang, W., & Liang, A. (2023). Potency and toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Hematology and Disorders. https://doi.org/10.58489/2836-3582/006
Vancouver
Ma Y, Li N, Lu J, Yang P, Li P, Zhang W, et al. Potency and toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Hematology and Disorders. 2023. doi:10.58489/2836-3582/006
BibTeX
@article{Ma2023,
author = {Ma, Yuting and Li, Nannan and Lu, Jinyuan and Yang, Pingping and Li, Ping and Zhang, Wenjun and Liang, Aibin},
title = {Potency and toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma},
journal = {Hematology and Disorders},
year = {2023},
doi = {10.58489/2836-3582/006}
}
EUVIMED